Market Tracker

07/27 5:16pm ET

Regeneron Pharmaceuticals Inc (NASDAQ:REGN)

508.41
Delayed Data
As of 4:00pm ET
 -7.22 / -1.40%
Today’s Change
325.35
Today|||52-Week Range
543.55
+38.50%
Year-to-Date
Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura
11:02am / Zacks.com - Paid Partner Content
Fears over a medical gold rush in cancer drug race
Jul 02 / FT.com - Paid Partner Content
Can Regeneron Pharma (REGN) Pull a Surprise in Q2 Earnings?
Jul 26 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close515.63
Today’s open515.77
Day’s range503.98 - 517.44
Volume958,059
Average volume (3 months)942,866
Market cap$54.8B
Dividend yield--
Data as of 4:00pm ET, 07/27/2017

Growth & Valuation

Earnings growth (last year)+39.49%
Earnings growth (this year)+13.71%
Earnings growth (next 5 years)+19.00%
Revenue growth (last year)+18.44%
P/E ratio61.5
Price/Sales8.79
Price/Book12.29

Competitors

 Today’s
change
Today’s
% change
SHPGShire-0.44-0.26%
VRTXVertex Pharmaceutica...-7.23-4.42%
BAXBaxter International...-0.84-1.37%
ZTSZoetis Inc-0.05-0.08%
Data as of 4:14pm ET, 07/27/2017

Financials

Next reporting dateAugust 3, 2017
EPS forecast (this quarter)$3.13
Annual revenue (last year)$4.9B
Annual profit (last year)$895.5M
Net profit margin18.42%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Leonard S. Schleifer
Chief Financial Officer &
Senior VP-Finance
Robert E. Landry
Corporate headquarters
Tarrytown, New York

Forecasts